(Q33862961)

29 July 2017

title

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass (English)

1 reference

29 July 2017

0 references

0 references

Robert C Bast

6

0 references

author name string

Brian Nolen

1

1 reference

29 July 2017

Liudmila Velikokhatnaya

2

1 reference

29 July 2017

Adele Marrangoni

3

1 reference

29 July 2017

Koen De Geest

4

1 reference

29 July 2017

Aleksey Lomakin

5

1 reference

29 July 2017

Anna Lokshin

7

1 reference

29 July 2017

language of work or name

English

0 references

publication date

24 March 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

117

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

440-445

1 reference

Development of a multimarker assay for early detection of ovarian cancer

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Role of eotaxin-1 signaling in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

A serum based analysis of ovarian epithelial tumorigenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Benign disorders of the ovary

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Guidelines for referral of the patient with an adnexal mass

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Establishment and characterization of a human ovarian small cell carcinoma, hypercalcemic type, cell line (OS-1) secreting PTH, PthrP and ACTH--special reference to the susceptibility of anti-cancer drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

The impact of subspecialty training on the management of advanced ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Ovarian cancer. The most lethal gynecologic malignancy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Validation of serum biomarkers for detection of early-stage ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Cushing's syndrome due to ovarian serous adenocarcinoma secreting multiple endocrine substances: a case report and immunohistochemical analysis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Diagnosis and management of the adnexal mass.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Association between Components of the Insulin-Like Growth Factor System and Epithelial Ovarian Cancer Risk

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873171

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

29 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

The effect of centralization of primary surgery on survival in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Diagnostic markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Circulating tumor markers in the monitoring of gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

CYFRA 21-1. A new marker in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20334903

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20334903

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2010.02.005

1 reference

29 July 2017

1 reference

29 July 2017

1 reference